Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06982378 · ClinicalTrials.gov registry record
GLP-1 RA on Liver OMICS in MASLD
A clinical trial, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- 30
- Enrollment target
NCT06982378 is a clinical trial that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 30 participants.
The verdict
NCT06982378 has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associated steatotic hepatitis (MASH). Hence, in T2DM, obesity, and MASLD, changes in the lipid profile occur, and they are interrelated. In this study, we aim to assess improvement in the lipidomic, its associated metabolic changes and evaluate the co-regulated genes in the liver tissue among patients with MASLD with intervention with GLP-1 RA, which has shown to benefit T2DM and obesity.
Interventions
- DRUG GLP-1 receptor agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06982378
The ClinicalTrials.gov registry entry for NCT06982378 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLP-1 receptor agonist is the first listed.
NCT06982378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06982378 about?
NCT06982378 is a clinical study titled "GLP-1 RA on Liver OMICS in MASLD". In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associ...
What is the current status of trial NCT06982378?
This trial is currently not yet recruiting. The enrollment target is 30 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT06982378?
The interventions under investigation include: GLP-1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT06982378?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.